Medtronic in the news

Medtronic finalized the exchange ratio for its MiniMed split-off, offering 4.5939 MiniMed shares for each Medtronic share, with the offer expiring on October 9, 2026.

Barclays initiated coverage of Medtronic with an Equal Weight rating and a $95 price target, citing opportunities in the medical sector and anticipating improved investor sentiment by 2027.

Felicia Kurz is the new VP and GM of cardiac ablation solutions at Medtronic, joining from Siemens Healthineers, as Medtronic's cardiac ablation business experiences significant growth.

Medtronic gained permanent CPT codes for two key systems, yet its stock is down this year, despite strong organic growth and an undervalued fair price.

Medtronic PLC's stock underperformed its competitors on Tuesday, according to MarketWatch Automation.

Medtronic's fiscal year 2026 impact report highlights serving over 82 million patients, significant R&D investment, new product approvals including the Hugo™ robotic system, and progress in environmental and social initiatives.

Julissa Rios and La Nueva Esperanza, a Spanish-language cancer support group, were honored as the Medtronic Game Changer for their two decades of service to Spanish-speaking individuals and families impacted by cancer.

Medtronic's $4 billion offer to swap its shares for those of its MiniMed diabetes business faces hurdles, potentially impacting Medtronic's share count and gross margins if the separation stalls.

MiniMed Group's stock is experiencing volatility due to arbitrage trading related to Medtronic's split-off offer, despite strong underlying business and analyst upgrades, but faces challenges with profitability and cash burn.

Medtronic stock outperformed the broader market, with future earnings projected to decline but revenue expected to grow, while trading at a discount compared to its industry.

Medtronic's first-quarter fiscal 2027 revenue reached $9.8 billion, a 13.7% increase, driven by strong cardiovascular growth, leading to raised full-year guidance, while the company continues to separate its diabetes business despite some uncertainty.

Medtronic's VenaSeal device demonstrated an 88.1% ulcer healing rate in a two-year study and achieved 96% U.S. insurance coverage for venous leg ulcers.

The article discusses McCormick, UnitedHealth Group, and Medtronic as dividend stocks well-suited for investors seeking stable income in a high-interest-rate environment.

Medtronic announced new clinical evidence for its VenaSeal‒ closure system in chronic venous disease, following expanded U.S. payer coverage.

Medtronic is showing improved growth and raising its financial guidance for fiscal 2027, making its stock more appealing to investors after years of slow growth.

Medtronic, a healthcare technology company, is experiencing accelerated business growth, particularly in its cardiac ablation solutions, which is shifting the focus from its long-standing dividend streak to its growth potential.

Medtronic's stock price, despite recent investments like a $700 million robotics partnership, may be undervalued compared to its projected future cash flows.

Medtronic's $4 billion stock exchange offer for MiniMed Group shares has become less attractive due to a recent drop in MiniMed's stock price.

Medtronic's shares declined by 6.4% despite the company reporting better-than-expected Q1 fiscal 2027 earnings and strong revenue growth across all segments.

The AMA approved permanent CPT codes for Medtronic's Altaviva and Symplicity Spyral devices, which treat urinary incontinence and hypertension respectively, effective January 2028.